The Kidney Cancer Association held a "Survivors' Conference" on Saturday, April 16, 2016 at MD Anderson in Houston.

The KCA also kindly recorded a video (here).

I have reproduced particular slides of interest from Nizar Tannir's nccRCC presentation below:

• How do I treat my patients with nccRCC?
  • Chromophobe: Responds to VEGFR-TKI / mTORi
  • RMC
    • Initial chemo as in TCC
    • Cytoreductive nephrectomy when feasible
    • Clinical Trials
  • Sarcomatoid: Gemcitabine based chemo +/- TKI; Clinical Trials (possibly highly responsive to immune checkpoint inhibitors)
  • All others
    • Clinical Trials
• Ongoing Clinical Trials for Papillary RCC
  • NCT01688973, 
  • NCT01524926, 
  • NCT02495103, 
  • NCT02019693, 
  • NCT01130519, 
  • NCT02489695, 
  • NCT02127710, 
• Ongoing Clinical Trials for nccRCC
  • NCT01399918
  • NCT01538238
  • NCT02504892
  • NCT01767636
  • NCT02601950
  • NCT01672775
  • MD Anderson - Cabozantinib vs. Sunitinib
  • MD Anderson - Pembrolizumab in RMC
• Conclusions
  • There is no established standard of care for nccRCC
    • Anti-VEGF TKIs are less effective in nccRCC compared with ccRCC
    • Temsirolimus is a poor standard of care for poor-risk disease
    • There may be a role for c-MET inhibitors in patients with germline mutation of c-MET in papillary RCC
    • The role of cytoreductive nephrectomy is not defined
  • All patients with metastatic nccRCC should be referred for enrollment on clinical trials
  • Data are now available from TCGA to develop rational targeted therapies based on relevant targets in chromophobe and papillary RCC
  • Transformative biology-driven trials are needed to improve clinical outcome
  • Trials with immune checkpoint inhibitors are planned